KSPH.F Stock Overview
Researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Kissei Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥25.00 |
| 52 Week High | JP¥25.00 |
| 52 Week Low | JP¥19.32 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 27.88% |
| 5 Year Change | -7.41% |
| Change since IPO | 24.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| KSPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 2.2% |
| 1Y | n/a | 11.8% | 32.6% |
Return vs Industry: Insufficient data to determine how KSPH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KSPH.F performed against the US Market.
Price Volatility
| KSPH.F volatility | |
|---|---|
| KSPH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KSPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KSPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,779 | Mutsuo Kanzawa | www.kissei.co.jp |
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients.
Kissei Pharmaceutical Co., Ltd. Fundamentals Summary
| KSPH.F fundamental statistics | |
|---|---|
| Market cap | US$1.03b |
| Earnings (TTM) | US$70.11m |
| Revenue (TTM) | US$529.62m |
14.7x
P/E Ratio1.9x
P/S RatioIs KSPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KSPH.F income statement (TTM) | |
|---|---|
| Revenue | JP¥81.07b |
| Cost of Revenue | JP¥40.63b |
| Gross Profit | JP¥40.44b |
| Other Expenses | JP¥29.71b |
| Earnings | JP¥10.73b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 250.69 |
| Gross Margin | 49.88% |
| Net Profit Margin | 13.24% |
| Debt/Equity Ratio | 0.6% |
How did KSPH.F perform over the long term?
See historical performance and comparison